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Abstract
Background: A number of publications have reported the use of microarray technology to identify gene
expression signatures to infer mechanisms and pathways associated with systemic lupus erythematosus (SLE) in
human peripheral blood mononuclear cells. However, meta-analysis approaches with microarray data have not
been well-explored in SLE.
Methods: In this study, a pathway-based meta-analysis was applied to four independent gene expression
oligonucleotide microarray data sets to identify gene expression signatures for SLE, and these data sets were
confirmed by a fifth independent data set.
Results: Differentially expressed genes (DEGs) were identified in each data set by comparing expression microarray
data from control samples and SLE samples. Using Ingenuity Pathway Analysis software, pathways associated with
the DEGs were identified in each of the four data sets. Using the leave one data set out pathway-based meta-
analysis approach, a 37-gene metasignature was identified. This SLE metasignature clearly distinguished SLE
patients from controls as observed by unsupervised learning methods. The final confirmation of the metasignature
was achieved by applying the metasignature to a fifth independent data set.
Conclusions: The novel pathway-based meta-analysis approach proved to be a useful technique for grouping
disparate microarray data sets. This technique allowed for validated conclusions to be drawn across four different
data sets and confirmed by an independent fifth data set. The metasignature and pathways identified by using this
approach may serve as a source for identifying therapeutic targets for SLE and may possibly be used for diagnostic
and monitoring purposes. Moreover, the meta-analysis approach provides a simple, intuitive solution for combining
disparate microarray data sets to identify a strong metasignature.
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Microarrays are powerful tools with capability of mea-
suring the transcript abundance of tens of thousands of
genes simultaneously in biological samples. Microarray
technology has matured over the past 15 years and is
now employed for the study of gene expression signa-
tures associated with disease [1-3]. The clinical utility of
microarrays as prognostic tools can be evidenced by the
approval of the US Food and Drug Administration
(FDA) of a customized microarray, MammaPrint™
(Agendia, Amsterdam, The Netherlands) for predicting
the outcomes in breast cancer patients on the basis of a
70-gene expression signature [4].
Some of the challenges associated with identification
of gene expression signatures that differentiate the dis-
ease state from healthy controls are the availability of
samples, sample size, heterogeneous data sets, and
reproducibility. Thus, robustness of the gene expression
signature derived from one study needs to be validated
by other independent studies, preferably with large sam-
ple sizes. In practice, however, several studies with rela-
tively small sample sizes are often used to identify gene
expression signatures. In these circumstances, it is bene-
ficial to combine the results of several individual studies
using meta-analysis. This process enhances statistical
power in identifying more robust and reliable gene
signatures.
Several meta-analysis approaches have been proposed
specifically for handling heterogeneous data sets. For
example, Rhodes et al. [5] used the approach of utilizing
P values of genes across studies to identify gene expres-
sion signatures that differentiate cancer tissues from
normal tissues and to predict poor or good patient out-
comes. Choi et al. [6] used an effect size estimate
approach in a meta-analysis of two cDNA microarray
data sets, human hepatocellular carcinoma and prostate
cancer, to identify a transcriptional signature for cancer.
A Bayesian approach was used by Wang et al. [7], who
performed microarray studies on three different plat-
forms and combined them to study differences in gene
expression between B-cell chronic lymphocytic leukemia
and normal B cells. Shen et al. [8] suggested a Bayesian
mixture model incorporating the probability of expres-
sion measure.
Most of the currently used meta-analysis approaches
first identify a set of commonly probed genes across stu-
dies and then derive a gene expression signature from
these. A shortcoming of this approach is a potential loss
of valuable information from individual data sets during
the combining process. Thus, we propose a pathway-
based meta-analysis approach whereby differentially
expressed genes (DEGs) from individual studies are
selected using a combination of P value and fold change
and the results are combined at the pathway level instead
of at the gene level (see Figure 1 and Methods). Addition-
ally, while most other methods perform very little valida-
tion or rely solely on the biological plausibility of the
obtained results to serve as validation, the approach pro-
posed here includes statistical validation through the
leave one data set out permutation method. The results
are further confirmed using an independent data set.
A number of authors have reported the use of micro-
array technology to identify gene expression signatures
in systemic lupus erythematosus (SLE) [9-14], mechan-
isms underpinning SLE [15-17], and pathways related to
SLE [18-20]. However, meta-analysis approaches have
not been explored sufficiently in the study of SLE
microarray data [21]. In the present study, the pathway-
based meta-analysis method was applied to four inde-
pendent gene expression oligonucleotide microarray
data sets to identify gene expression signatures for SLE.
These data sets were generated from peripheral blood
mononuclear cell (PBMC) samples from SLE patients
and healthy controls. The resulting signatures were then
confirmed by testing on a fifth independent data set.
Methods
Data collection
Data sets from five independent microarray studies
comparing PBMC samples from SLE patients with those
from healthy individuals were obtained from prominent
SLE researchers. These data sets are referred to as data
sets 1, 2, 3, 4, and 5. Data sets 1, 2, 4, and 5 are asso-
ciated with peer-reviewed publications (11-14). Data set
3 is composed of unpublished data. Three of the studies
(studies 1, 4, and 5) included only pediatric patients,
while the remaining two included only adults. All stu-
dies employed the Affymetrix GeneChipmicroarray plat-
form (Affymetrix, Inc., Santa Clara, CA, USA) but the
v e r s i o n so ft h ea r r a yt y p ev a r i e d( T a b l e1 ) .I nt h ec a s e
of two different array types used for the same study
(that is, data sets 1 and 2), we treated them as separate
data sets (data sets 1a, 1b, 2a, and 2b) during the meta-
analysis. Raw data in the form of Affymetrix CEL files
were provided for studies 1, 2, 3, and 5. For data set 4,
however, expression values for a short-listed set of genes
were provided. While data sets 1 to 4 were used in the
meta-analysis workflow, data set 5 served as an indepen-
dent data set to validate the gene signature derived from
the meta-analysis.
Workflow of the pathway-based meta-analysis approach
The overall workflow of the pathway-based meta-analysis
is summarized in Figure 1. The meta-analysis used a leave
one data set out validation process. Both principal compo-
nent analysis (PCA) and hierarchical cluster analysis
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out cross-validation results. Last, the combined meta-sig-
nature obtained from the 4 data sets was validated against
an independent fifth data set (data set 5).
For the individual quality control and data analysis
steps mentioned below, each data set was considered
separately. Additionally, since data sets 1 and 2 used
two chip types each, they were considered as four differ-
ent data sets (1a, 1b, 2a, and 2b) for the initial analysis.
Quality control
Quality assessment was done for each data set using the
Genedata Expressionist (Genedata, San Francisco, CA,
USA) [22] (Figure 1, step 1). Only one sample in data
set 2a was discarded from further analysis, because it
had too high a value for defective area percentage.
Individual data processing and analysis
Following quality control assessment, each data set was
analyzed individually using the ArrayTrack™ tool (US
Food and Drug Administration’s National Center for
Toxicological Research, Jefferson, AR, USA) [23]. Array-
Track is a comprehensive tool for microarray data sto-
rage, analysis, and interpretation that has been
developed at the FDA’s National Center for Toxicologi-
cal Research. To maintain consistency during the
Figure 1 Pathway based meta-analysis process (described for scenario I in Tables 2 and 3). The meta-analysis approach involved three
major steps: individual analysis of the data sets, meta-analysis at the pathway level, and validation of the signature. Figure 1 represents the
process for one scenario. For each scenario, three of the data sets were used to generate the signature and the fourth one was used for testing
of the signature. The four data sets were switched around to create four scenarios (see Table 2). The signatures from each scenario were then
combined to provide a meta-signature, which was confirmed by the fifth data set.
Table 1 Information on data sets used for meta-analysis
a
Data set Platform Type of data Samples, n Source
Data set 1 1a: HG U133A 1b: HG U133B Pediatric PBMC 59 (38 SLE, 21 controls) Allantaz et al. [11]
Data set 2 2a: HG U95 Av1 2b: HG U95 Av2 Adult PBMC 90 (48 SLE, 42 controls) Baechler et al. [12]
Data set 3 HG U133 Plus 2 Adult PBMC 58 (44 SLE, 14 controls) Unpublished data
Data set 4 HG U95 Av1 Pediatric PBMC 39 (30 SLE, 9 controls) Bennett et al. [35]
Data set 5 1a: HG U133A 1b: HG U133B Pediatric PBMC 57 (47 SLE, 10 controls) Chaussabel et al. [14]
aPBMC, peripheral blood mononuclear cell; SLE, systemic lupus erythematosus.
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methods, statistical tests, and parameters were used with
all data sets. First, all data sets except data set 4 were
normalized using Robust Multi-array Analysis. Then
Welch’s t test was performed on each data set individu-
ally. The P value and fold change filters (0.01 and 1.5,
respectively) were used to identify a unique list of DEGs
from each data set (Figure 1, step 2). This list repre-
sented genes that were either notably upregulated or
downregulated in the PBMCs of SLE patients when
compared to the PBMCs of healthy controls. Each DEG
list was then used to identify biological pathways signifi-
cantly represented in SLE samples compared to the
healthy controls (P < 0.01) in each data set (Figure 1,
step 3). This pathway analysis was done using Ingenuity
Pathway Analysis (IPA) software (Ingenuity Systems
Inc., Redwood City, CA, USA).
Meta-analysis
Pathways common to all of the data sets were identified
from the individual lists of pathways enriched in SLE
patients compared to healthy controls (one for each data
set) (Figure 1, step 4). The resulting list of pathways was
indicative of processes significantly affected in all of the
SLE data sets and comprised a pathway signature repre-
sentative of all data sets and of the disease. From this com-
mon pathway signature, gene markers that met all of the
following criteria were selected: (1) exhibited a fold change
greater than 2 in at least one of the data sets (stringency
increased from 1.5-fold to 2-fold to obtain a robust signa-
ture), (2) present in the DEG list in at least one of the data
sets, and (3) involved in at least one of the commonly
enriched pathways (Figure 1, step 5). These DEGs com-
posed the collective signature (Figure 1, step 6).
Validation with the leave one data set out permutation
method
To validate this technique, a leave one data set out per-
mutation approach was employed (Figure 1, step 7). The
meta-analysis technique described above was reiterated
four times, each time leaving out one of the four data
sets (data sets 1 to 4) and performing the analysis using
the remaining three data sets. This gave rise to four dif-
ferent scenarios (Table 2). The gene signature obtained
using the three data sets (for example, data sets 1 to 3)
was then applied to the data set left out (for example,
data set 4). Unsupervised visualization techniques such
as PCA and HCA were performed to examine how well
the signature could differentiate SLE patients from
healthy controls (Figures 2 and 3).
Metasignature development
Gene markers were generated for each of the four sce-
narios as described in the Meta-analysis section. Gene
markers present in at least three of the four scenarios
were grouped to comprise a 37-gene metasignature.
Confirmation using a fifth independent data set
Confirmation of the final 37-gene metasignature was
done using an independent fifth data set, data set 5
(Figure 1, step 8). Again, PCA and HCA were carried out
to evaluate the ability of the metasignature to differentiate
SLE patients from healthy controls in this independent
data set (Figure 4).
Results and discussion
Individual data sets of SLE and healthy control data sets
derived from Affymetrix microarrays were analyzed
using ArrayTrack following quality control (Figure 1,
step 1) and normalization procedures. DEGs for indivi-
dual data sets were identified using a P value cutoff of
0.01 and a fold change cutoff of 1.5 (Figure 1, step 2).
Biological pathways identified in SLE patients through the
leave one data set out permutation method
After applying the leave one data set out approach for
each of the four scenarios (Table 2), commonly enriched
biological pathways were identified using IPA software
(Table 3). Three biological pathways were consistently
enriched in SLE patients in all four scenarios: interferon
(IFN) signaling, interleukin (IL)-10 signaling, and gluco-
corticoid receptor signaling. An additional pathway,
LXR/RXR signaling, was identified only in scenario IV.
Previous studies have provided evidence of increased
autoimmunity in patients undergoing IFN treatment [24].
More specifically, there is evidence of women developing
SLE during IFN-a treatment [25]. Several studies have
shown upregulation of the IFN signaling pathway in SLE
patients [9,12,17,26-30]. Therefore, it is understandable that
IFN signaling appears to be affected across all data sets.
IL-10 signaling appears to be dysregulated and may be
indicative of the inflammatory processes involved in
Table 2 Scenarios for leave one data set out validation
Scenario I Scenario II Scenario III Scenario IV
Data set 1 (a and b) Data set 2 (a and b) Data set 1 (a and b) Data set 1 (a and b)
Data set 2 (a and b) Data set 3 Data set 3 Data set 2 (a and b)
Data set 3 Data set 4 Data set 4 Data set 4
Test: Data set 4 Test: Data set 1 (a and b) Test: Data set 2 (a and b) Test: Data set 3
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and activates the JAK-STAT signaling pathway, which is
the key IFN signaling mechanism [31]. In support of the
hypothesis that IL-10 is involved in SLE, IL-10 has been
identified as one of risk loci for SLE in a large genome-
wide association study [32].
Glucocorticoid receptors are also believed to influence
cytokine signaling and may be indirectly involved in the
pathways underpinning SLE [33]. In fact, glucocorticoids
are routinely used in the treatment of SLE patients.
Genes differentially expressed in SLE
Each of the four scenarios produced a gene signature:
scenario I produced a signature comprising 51 genes,
scenario II produced a signature with 31 genes,
scenario III produced a signature with 34 genes, and
scenario IV produced a signature with 28 genes. These
DEGs represent the three main SLE disease pathways
(IFN signaling, IL-10 signaling pathway, and glucocor-
ticoid signaling pathways) as discussed in the section
above.
A separate analysis of the pediatric and adult data sets
used to identify DEGs and pathways in the two popula-
tions was conducted. Similar gene expression patterns
were observed in adult and pediatric populations,
although the extent of upregulation of some of the
genes was higher in the pediatric data sets (unpublished
results).
A                    B 
 
  C        D  
Figure 2 Principal component analysis from all scenarios. There is a clear distinction between healthy samples and systemic lupus
erythematosus (SLE) patients, shown in blue and red, respectively. (A) Scenario I. (B) Scenario II. (C) Scenario III. (D) Scenario IV. The Systemic
Lupus Erythematosus Disease Activity Index (SLEDAI) scores indicate that most SLE patients exhibiting close to normal gene expression are in
remission (SLEDAI score 0) or have low disease activity (SLEDAI scores 2 and 3).
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For each scenario, the signature obtained using the three
data sets was applied to the fourth data set to observe how
effectively the expression of the signature genes could dis-
tinguish between the SLE and healthy populations.
The PCAs and HCAs obtained for each scenario are
presented in Figures 2 and 3, respectively. The PCA and
HCA produced similar and consistent results. Grouping
of samples based on the expression of signature genes
alone produced a clear distinction between SLE patients
A          B  
  
    
C      D  
Figure 3 Hierarchical clustering analysis for all scenarios. Blue branches indicate healthy samples, and red branches indicate SLE patients.
(A) Scenario I. (B) Scenario II. (C) Scenario III. (D) Scenario IV.
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signatures derived by using the leave one data set out
permutation approach in the four scenarios (Table 2)
can potentially identify a robust gene expression signa-
ture for SLE.
Gene expression signatures for SLE and Systemic Lupus
Erythematosus Disease Activity Index scores
The Systemic Lupus Erythematosus Disease Activity
Index (SLEDAI) is a validated scoring system that can
be used to describe the range of disease activity and
comprises a weighted score calculated by the presence
or absence of 24 symptoms. The association of SLEDAI
scores to expression profiles of SLE patients was evalu-
ated. While the majority of the samples were grouped
into their respective classes (SLE or control; see Figure
2), 12 SLE patients exhibited expression profiles similar
to the control samples. On closer examination of these
samples, it was found that the scores for nine of the
patients indicated that theyw e r ee i t h e ri nr e m i s s i o n
(SLEDAI score 0) or had mild activity of the disease
(SLEDAI score 2 or 3). These findings lend further cre-
dence to the ability of the pathway-based meta-analysis
approach used here in distinguishing SLE patients from
healthy controls. Correlation between SLEDAI scores
and gene expression signatures has also been reported
in the literature [9,26,34].
Metasignature for SLE
A 37-gene signature was generated by the meta-analysis
workflow (Table 4). Many IFN-induced genes involved
in the IFN signaling pathway (Figure 5), such as IFIT1,
IFIT3, IFITM1, IFIT35, MX1, and OAS1, were present in
the signature. Overexpression of IFN-regulated genes in
PBMCs of SLE patients has been reported in several
publications [9,15,26,35-37]. In addition to genes
involved in the IFN signaling pathway, genes in cytokine
signal transduction (SOCS1 and SOCS3)w e r ea l s o
among the DEGs in SLE patients. Differential expression
of many other biomarkers associated with inflammatory
AB
SLEDAI Score 2
Figure 4 Validating the 37-gene signature using independent data set 5. (A) Hierarchical clustering analysis shows blue branches indicating
healthy samples and red branches indicating SLE patients. (B) Principal component analysis with healthy samples shown in blue and SLE
patients shown in red.
Table 3 Biological pathways commonly and significantly enriched in the four scenarios
a
Scenario I Scenario II Scenario III Scenario IV
IPA pathways IPA pathways IPA pathways IPA pathways
IL-10 signaling IL-10 signaling IL-10 signaling IL-10 signaling
Interferon signaling Interferon signaling Interferon signaling Interferon signaling
Glucocorticoid receptor
signaling
Glucocorticoid receptor
signaling
Glucocorticoid receptor
signaling
Glucocorticoid receptor
signaling
LXR/RXR signaling
aIPA, Ingenuity Pathway Analysis software; IL, interleukin; LXR, liver X receptor; RXR, retinoid X receptor.
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was also observed, as shown in Table 4.
Confirmation of the metasignature using an independent
data set
This signature was applied to an independent fifth data
set (data set 5) to evaluate its ability to distinguish the
SLE samples from the control samples. Figure 4 shows
that the signature demonstrated clear differentiation
between SLE patients and healthy controls. In the HCA
analysis, nine of ten healthy samples clustered together
and were clearly separated from the cluster of SLE sam-
ples (Figure 4A). The PCA analysis also showed that the
majority of the SLE samples and healthy samples were
grouped separately (Figure 4B). The one SLE sample
that was clustered with the healthy samples had a SLE-
DAI score of 2, confirming our earlier observations with
different data sets (Figure 2).
Conclusions
The novel pathway-based meta-analysis approach
proved to be a useful technique for grouping disparate
microarray data sets. This technique allowed for vali-
dated conclusions to be drawn across four different data
sets and confirmed by testing on an independent fifth
data set. Since the metasignature was obtained from
pathways that were enriched in SLE samples across all
of the data sets, it is highly representative of biological
pathways related to SLE. The metasignature produced
here may serve as a source for identifying potential
Table 4 Signature genes and their functionalities
Functionality Genes from signature
Interferon signaling and
interferon-induced or interferon-
regulated genes
IFI35, IFIT1, IFIT3, IFITM1, MX1, OAS1,
STAT1, STAT2, CCL2, CXCL1, SOCS1,
SOCS3
Inflammatory and immune
response
CCL3, CCR1, CD163, FCGR1A, IL1R2,
IL1B, IL1RN, IL-8, NFAT5, TRA@,
MAP2K3, MAP2K6, SMAD3, FCGR2A,
FCGR2B, NFKBIA
Cellular proliferation and
differentiation
CDKN1C, CDK1A, DUSP1, EP300, FOS,
JUN, PRKACA, PRKACB
Protein folding SLP1
Figure 5 Interferon signaling pathways. Interferon-a, interferon-b, and interferon-g signaling pathways are shown. The genes in blue represent
differentially expressed genes that are part of the SLE metasignature.
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Page 8 of 10therapeutic targets for SLE. Also, with further refine-
ment, it might be made clinically more intuitive, which
may also prove to be useful for the diagnosis and moni-
toring of SLE. Moreover, the meta-analysis approach
outlined here provides a simple and intuitive solution
for combining disparate microarray data sets to identify
a robust metasignature.
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